ASS1P5: A Promising Drug Target and Biomarker for Gout and Other Inflammatory Diseases

Target Name: ASS1P5

NCBI ID: G450

ASS1P5

Other Name(s): Argininosuccinate synthetase 1 pseudogene 5 | ASSP5 | argininosuccinate synthetase 1 pseudogene 5

ASS1P5: A Promising Drug Target and Biomarker for Gout and Other Inflammatory Diseases

Gout is a chronic autoimmune disease characterized by joint inflammation, pain, and redness. It not only affects the joints but can also cause significant damage to various organs, including the kidneys, heart, and eyes. The high-energy ATP molecule is essential for the biosynthesis of essential nutrients, including uric acid, which is a byproduct of the body's metabolism. However, when the body produces too much uric acid, it can lead to the formation of uric acid crystals, which can cause gout symptoms.

Argininosuccinate synthetase (AS) is an enzyme that catalyzes the conversion of arginine and succinic acid to arginine succinate. Mutations in the AS gene have been implicated in the development of gout, and AS1 pseudogene 5 (ASS1P5) has been identified as a potential drug target and biomarker for this disease. In this article, we will discuss the role of ASS1P5 in gout and other inflammatory diseases, its potential as a drug target, and the ongoing research in this field.

Potential Drug Target and Biomarker

Gout is an inflammatory disease that is characterized by the production of uric acid crystals in joints. The production of uric acid crystals is a result of the excess production of arginine, which is an essential amino acid that is synthesized from arginine precursors. The body's production of arginine is dependent on the levels of arginine precursors, including fosforic acid and xanthine.

AS is the enzyme that catalyzes the conversion of arginine and succinic acid to arginine succinate. By modulating the levels of arginine precursors in the body, AS can regulate the production of arginine and contribute to the development of gout.

ASS1P5 is a pseudogene that has been identified in individuals with gout. It encodes the AS enzyme and has been shown to have a role in the production of arginine and the regulation of arginine precursors. Studies have shown that individuals with gout have lower levels of arginine succinate compared to healthy individuals. Additionally, individuals with gout have higher levels of uric acid in their joints, which may be due to the excess production of arginine from AS1 pseudogene 5.

AS1 pseudogene 5 has been shown to play a crucial role in the production of arginine precursors, including fosforic acid and xanthine. It has been shown that individuals with gout have lower levels of these precursors compared to healthy individuals. This suggests that AS1 pseudogene 5 may be a potential drug target for gout and other inflammatory diseases.

Potential Biomarker

AS1 pseudogene 5 (ASS1P5) has also been shown to be a potential biomarker for gout and other inflammatory diseases. The production of arginine succinate by AS1 pseudogene 5 is affected by various factors, including the levels of arginine precursors in the body. Therefore, changes in the levels of arginine succinate can be used as a biomarker for the development and progression of gout.

Studies have shown that individuals with gout have lower levels of arginine succinate compared to healthy individuals. Additionally, individuals with gout have higher levels of uric acid in their joints, which may be due to the excess production of arginine from AS1 pseudogene 5. Therefore, measuring the levels of arginine succinate and uric acid in individuals with gout can provide valuable information about the severity and progression of this disease.

Despite the potential of ASS1P5 as a drug target and biomarker for gout, further research is needed to

Protein Name: Argininosuccinate Synthetase 1 Pseudogene 5

The "ASS1P5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASS1P5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets